Familial B-cell Lymphoproliferative Disorders (Familial_LPD)

May 7, 2024 updated by: Geffen Kleinstern, University of Haifa

Epidemiology of Familial B-cell Lymphoproliferative Disorders

This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Jewish and Arab LPD families with at least 2 family members with LPD.

Description

Inclusion Criteria:

  • Patient inclusion criteria:

Patients must have LPD and must have a family history of LPD. LPD patients who signed an informed consent to participate in the study.

Criteria for the inclusion of relatives of patients:

Relatives must be related by blood to LPD patients or unrelated (for control group).

Relatives who signed an informed consent to participate in the study.

Exclusion Criteria:

  • Pregnant women, special populations and those lacking judgment will not be included

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bnai Zion Medical Center
Other: No intervention
No intervention
Tel Aviv Sourasky Medical Center - Ichilov Hospital
Other: No intervention
No intervention
Galil Medical Center
Other: No intervention
No intervention
Ziv Medical Center
Other: No intervention
No intervention
Emek Medical Center
Other: No intervention
No intervention
Beilinson Hospital
Other: No intervention
No intervention
Meir Medical Center
Other: No intervention
No intervention
Kaplan Medical Center
Other: No intervention
No intervention
Sheba Medical Center
Other: No intervention
No intervention
Rambam Medical Center
Other: No intervention
No intervention
Shaare Zdek Medical Center
Other: No intervention
No intervention
Hadassah Medical Center
Other: No intervention
No intervention
Shamir Medical Center (Assaf Harofeh)
Other: No intervention
No intervention
Soroka Medical Center
Other: No intervention
No intervention
Assuta Ashdod Hospital
Other: No intervention
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of familial LPD in Israel
Time Frame: 5 years
5 years
Association between medical history and genetic variants and the risk of familial LPD
Time Frame: 5 years
5 years
Risk of clinical outcomes among familial LPD and family members
Time Frame: 15 years
15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Haifa

Collaborators

Bnai Zion Medical Center

Investigators

  • Principal Investigator: Geffen Kleinstern, PhD, University of Haifa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2024

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2040

Study Registration Dates

First Submitted

January 30, 2023

First Submitted That Met QC Criteria

January 30, 2023

First Posted (Actual)

February 8, 2023

Study Record Updates

Last Update Posted (Actual)

May 8, 2024

Last Update Submitted That Met QC Criteria

May 7, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FamilialLPD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoproliferative Disorders

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe